Health care delays (postponement of medical care) are a significant barrier to optimal care for cancer survivors, particularly among adolescent and young adults (AYAs). 1 - 3 Despite overall ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly ...

Background: Optimal first line therapy for patients with metastatic melanoma is an immunotherapy regimen containing an anti-PD1 antibody, regardless of tumour BRAF mutation status. Anti-PD1 antibodies ...

Background: Axi-cel is an autologous anti-CD19 CAR T-cell therapy that demonstrated durable, long-term efficacy and manageable safety in R/R LBCL. However, there is paucity of data using axi-cel in ...

Background: This study aimed to systematically characterize the heterogeneity of PSMA expression in hormone-sensitive prostate cancer (HSPC) and metastatic castration-resistant prostate cancer (mCRPC) ...

Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain ...

Background: Amivantamab is a bispecific antibody that was granted accelerated approval by the FDA in May 2021 for the treatment of non-small cell lung cancer (NSCLC) with epidermal growth factor ...

The MD Anderson dose-escalated, hypofractionated prostate radiation study was a phase III randomized trial comparing conventionally fractionated intensity-modulated radiation therapy (CIMRT, 75.6 Gy ...

The Pediatric Holistic Evaluation of Auditory Risk (PedsHEAR) model architecture used several machine learning approaches followed by an ensemble predictor. The primary end point was post-treatment ...

Radiation dose escalation for locally advanced non–small cell lung cancer (LA-NSCLC) has been challenged by toxicity concerns. The Scandinavian phase III multicenter dose-escalation trial NARLAL2 ...

Not surprisingly, women receiving the CDK4/6 inhibitors in the adjuvant setting had an increased probability of nausea, hair thinning, hepatic function abnormalities, fatigue, infection risk, and ...